RT Journal Article
SR Electronic
T1 Successful Application of Wastewater-Based Epidemiology in Prediction and Monitoring of the Second Wave of COVID-19 in India with Fragmented Sewerage Systems- A Case Study of Jaipur (India)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.11.21263417
DO 10.1101/2021.09.11.21263417
A1 Arora, Sudipti
A1 Nag, Aditi
A1 Kalra, Aakanksha
A1 Sinha, Vikky
A1 Meena, Ekta
A1 Saxena, Samvida
A1 Sutaria, Devanshi
A1 Kaur, Manpreet
A1 Pamnani, Tamanna
A1 Sharma, Komal
A1 Saxena, Sonika
A1 Shrivastava, Sandeep K
A1 Gupta, A. B.
A1 Li, Xuan
A1 Jiang, Guangming
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.11.21263417.abstract
AB The present study tracked the city-wide dynamics of severe acute respiratory syndrome-corona virus 2 (SARS-CoV-2) RNA in the wastewater from nine different wastewater treatment plants (WWTPs) in Jaipur during second wave of COVID-19 out-break in India. A total of 164 samples were collected weekly between February 19th and June 8th, 2021. SARS-CoV-2 was detected in 47.2% (52/110) influent samples and 37% (20/54) effluent samples. The increasing percentage of positive influent samples correlated with the city’s increasing active clinical cases during the second wave of COVID-19 in Jaipur. Furthermore, WBE based evidence clearly showed early detection of about 20 days (9/9 samples reported positive on April 20th, 2021) prior to the maximum cases & maximum deaths reported in the city on May 8th, 2021. The present study further observed the presence of SARS-CoV-2 RNA in treated effluents at the time window of maximum active cases in the city even after tertiary disinfection treatments of UV & Chlorine. The average genome concentration in the effluents and removal efficacy of six commonly used treatments; Activated Sludge Treatment + Chlorine disinfection (ASP + Cl2), Moving Bed Biofilm Reactor (MBBR) with Ultraviolet radiations disinfection (MBBR + UV), MBBR + Chlorine (Cl2), Sequencing Batch Reactor (SBR) and SBR + Cl2 were compared with removal efficacy of SBR + Cl2 (81.2%)> MBBR + UV (68.8%) > SBR (57.1%) > ASP (50%) > MBBR + Cl2(36.4%). The study observed the trends & prevalence of four genes (E, RdRp, N, and ORF1ab gene) based on two different kits and found that prevalence of N> ORF1ab >RdRp> E gene, suggested that the effective genome concentration should be calculated based on the presence/absence of multiple genes. Hence, it is imperative to say that using a combination of different detection genes (E, N, RdRp & ORF1ab genes) reduce false positives in WBE.HighlightsSuccessful application of WBE with prediction of 14-20 days for COVID-19 in JaipurA comparison of SARS-CoV-2 RNA removal efficacy of 9 WWTPs was investigatedSBR showed better performance than MBBR with SARS-CoV-2 RNA removal from wastewaterPresence of SARS-CoV-2 in effluents even after UV and Chlorine disinfectionUsing a combination of different detection genes reduce false positives in WBECompeting Interest StatementThe authors have declared no competing interest.Funding StatementFunding: This work was financially supported by the Internal Mural Grants (IMG) Fund (BIBT/IRSC/IMG/2020-21/036), supported by IRSC, Dr. B. Lal Institute of Biotechnology, Jaipur and Dr. Xuan Li was also supported by the Australian Research Council Discovery project (DP190100385).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethical committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the necessary Data is available in the manuscript.